Thursday, 04 June 2026 07:59 AM
Class Action
NEWTOWN SQUARE, PA / ACCESS Newswire / June 4, 2026 / Investor protection law firm Kaskela Law LLC is investigating potential legal claims on behalf of stockholders of Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), formerly known as AlloVir, Inc. (ALVR), who received their Kalaris shares in connection with Kalaris' March 2025 merger with AlloVir.
Since the time the merger closed in March 2025, shares of Kalaris' stock have declined in value from over $9.00 per share to a current trading price of less than $5.00 per share, a decline of nearly 45% in value.
Former AlloVir (ALVR) shareholders whose ALVR shares were exchanged for Kalaris (KLRS) shares in March 2025 are encouraged to contact Kaskela Law LLC lead investigative attorney Adrienne Bell, Esquire for additional information about this investigation and their legal rights and options at (484) 229 - 0750, by email at [email protected], or by filling out the firm's online form at:
https://kaskelalaw.com/case/allovir-kalaris/
ABOUT KASKELA LAW:
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis (i.e., the firm's clients are never responsible for any out-of-pocket costs for legal representation). Since 2020, the firm has helped to recover over $500 million for investors. For additional information about Kaskela Law LLC, including the firm's recent notable recoveries for investors, please visit www.kaskelalaw.com.
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
([email protected])
Adrienne Bell, Esq.
([email protected])
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 - 0750
This communication may constitute attorney advertising in certain jurisdictions.
SOURCE: Kaskela Law LLC